Elucidation of pharmacokinetics of remimazolam and metabolites before and after continuous administration of remimazolam - Elucidation of pharmacokinetics of remimazolam and metabolites before and after continuous administration of remimazolam

Department of Anesthesiology and Intensive Care Medicine, Hamamatsu University School of Medicine0 个研究点目标入组 40 人开始时间: 2020年8月17日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patients with severe respiratory, circulatory, central nervous system, digestive system, liver, kidney, hematopoietic functions, etc. 2. Emergency surgery 3. Patients scheduled to undergo surgery other than spine at the same time 4. Patients with a history of hypersensitivity to benzodiazepines or flumazenil 5. Patients with a history of hypersensitivity to remifentanil, fentanyl, rocuronium, sugammadex or other components of the drug required to maintain general anesthesia. 6. Patients with acute angle-closure glaucoma 7. Patients with myasthenia gravis 8. Shock patients, coma patients, acute alcoholics with suppressed vital signs 9. Patients who are prone to respiratory depression such as coma due to head injury or brain tumor 10. Patients with a history of seizures 11. Patients with bronchial asthma 12. Patients with organic abnormalities in the brain 13. Patients who used benzodiazepines within 1 week before surgery 14. Patients with a history of severe allergies 15. Patients who have a history of drug dependence or alcohol dependence 16. Pregnant patient 17. Lactating patients 18. Patients who are judged to have a lack of consent due to dementia and other factors 19. Patients who are judged to be excluded by other investigators/partners

发起方

Department of Anesthesiology and Intensive Care Medicine, Hamamatsu University School of Medicine